← all works
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Bladder and Urothelial Cancer Treatments
- Field
- Medicine
- Canadian institutions
- BC Cancer AgencyPrincess Margaret Cancer Centre
- Funders
- National Cancer InstituteEMD SeronoIpsenAstellas PharmaF. Hoffmann-La RocheEisaiSanofiAmgenPfizerGenentechCelgeneAstraZenecaEli Lilly and Company
- Keywords
- AtezolizumabMedicineMetastatic Urothelial CarcinomaClinical endpointOncologyInternal medicineCisplatinChemotherapyProgression-free survivalPhases of clinical researchResponse Evaluation Criteria in Solid TumorsCancerBladder cancerUrologyClinical trialUrothelial carcinomaImmunotherapyPembrolizumab
- Has abstract in OpenAlex
- no